Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies
- HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome. Bolognesi, E; Cimino, G; Diverio, D; Rapanotti, M C; D�Alfonso, S; Fleischhauer, K; Migliaretti, G; Momigliano-Richiardi, P // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p393
The majority of patients with acute promyelocytic leukemia (APL) possess either a bcr1 or a bcr3 type fusion between PML and RARa genes. The junction sequences may possibly be a target for immune response and influence susceptibility to the disease. In this case, HLA class I allele frequencies...
- HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Wetzler, M; Baer, M R; Stewart, S J; Donohue, K; Ford, L; Stewart, C C; Repasky, E A; Ferrone, S // Leukemia (08876924);Jan2001, Vol. 15 Issue 1, p128
Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based...
- Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? Pawelec, G; Wagner, W // Leukemia (08876924);Jan2001, Vol. 15 Issue 1, p192
Discusses whether HLA histocompatibility antigens HLA-DR4 and HLA-DRB1 alleles are associated with the decreased risk of chronic myeloid leukemia (AML). Investigation conducted regarding this association; Role of peptide binding with these alleles in decreasing risks of AML.
- HLA phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL. Tursz, Thomas; Hors, Jacques; Lipinski, Marc; Aamiel, Jean-Louis // British Medical Journal;5/13/1978, Vol. 1 Issue 6122, p1250
In recent years evidence has been produced to show the association of numerous diseases with individual HLA antigens. Theoretically, acute lymphoblastic leukaemia (ALL) was initially supposed to be likely to show such an association, since in mice the susceptibility to virus-induced leukaemia...
- HLA and Hogkin�s disease: reply to Taylor and Gokhale. Dorak, M T; Mills, K I; Poynton, C H; Burnett, A K // Leukemia (08876924);Jun97, Vol. 11 Issue 6, p892
Discusses the association between HLA antigens, leukemia and Hodgkin's disease. Consistent association of homozygosity for HLA antigens in hemopoietic malignancies; Role of HLA antigens in the etiology of Hodgkin's disease.
- Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Cortes, J; Fayad, L; Kantarjian, H; O�Brien, S; Lee, M-S; Talpaz, M // Leukemia (08876924);Apr98, Vol. 12 Issue 4, p455
Twenty to 25% of patients with chronic myelogenous leukemia (CML) treated with interferon-alpha (IFN-A) achieve a complete cytogenetic response (CCR). However, cells bearing rearrangement of BCR/ABL can still be detected many years after achieving a CCR despite the absence of clinical evidence...
- DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A*2402 resulting in loss of HLA allele expression. Sayer, D.C.; Smith, L.K.; Krueger, R.; Chrisitansen, F.T. // Leukemia (08876924);Jan2004, Vol. 18 Issue 1, p174
Presents a letter to the editor of "Leukemia" journal about an article describing the DNA sequence of HLA histocompatibility antigen typing of mutations in B cell acute lymphoblastic leukemia.
- HLA-DR antigen-negative acute myeloid leukemia. Wetzler, M; McElwain, B K; Stewart, C C; Blumenson, L; Mortazavi, A; Ford, L A; Slack, J L; Barcos, M; Ferrone, S; Baer, M R // Leukemia (08876924);Apr2003, Vol. 17 Issue 4, p707
Human leukocyte antigen (HLA) Class II antigens are variably expressed on acute myeloid leukemia (AML) blasts. The biological and clinical significance of HLA Class II antigen expression by AML cells is not known. Therefore, we sought to characterize cases of AML without detectable HLA-DR...
- Identification of natural killer cell receptor phenotypes associated with leukemia. Verheyden, S.; Bernier, M.; Demanet, C. // Leukemia (08876924);Dec2004, Vol. 18 Issue 12, p2002
Natural killer (NK) cells play a key role in defense against tumor cells that have the capacity to downregulate human leukocyte antigen (HLA) class I expression. It has been reported that leukemic cells can have downregulated expression of HLA class I molecules. The polymorphic nature of NK cell...